Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oridonin clathrate compound, and medicinal prepn. thereof

A technology of Rubescensin A and clathrate, which is applied in the direction of medical preparations containing active ingredients, non-active ingredients of polymer compounds, drug combinations, etc., and can solve the problem of low drug loading and encapsulation efficiency and complicated process , can not be applied and other problems, to achieve the effect of improving solubility and bioavailability, simple process and low production cost

Inactive Publication Date: 2007-04-18
SINOPHARM A THINK PHARMA
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent application 200510046253.3 provides a kind of oridonin liposome for the defects of low drug loading and encapsulation efficiency of the above-mentioned oridonin emulsion, indicating that it can increase the drug loading of the medicament
[0007] From the records of the above-mentioned prior patents, it can be seen that in order to stabilize the preparation, a relatively large amount of oil, emulsifier and isotonic agent must be added to the preparation of Rubescensin A emulsion, which is easy to introduce some allergenic ingredients
The earliest developed Rubescensin A emulsion is because it contains a lot of alcohol and oil, which is obviously sensitized in clinical use and cannot be applied.
The preparation of Rubescensin A liposome then requires a relatively large amount of packaging material (phospholipid), stabilizer, water-soluble carrier, etc.; from the perspective of industrial production, the preparation of pharmaceutical preparations in the form of microemulsions and liposomes requires production equipment High, especially after encapsulating the main drug, high-power emulsification equipment is required to make the encapsulation highly dispersed, such as high-pressure homogenization equipment, which makes the process more complicated; in addition, the main ones currently used in liposome preparation The raw material is still lecithin, and its quality has a great influence on the final liposome, so the lecithin used in the pharmaceutical industry is mainly imported
[0008] Therefore, processing oridonin into appropriate preparations at this stage, its complex process, high input equipment and high cost of raw materials constitute constraints for some small-scale pharmaceutical companies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oridonin clathrate compound, and medicinal prepn. thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Preparation of Oridonin Cyclodextrin Inclusion Compound

[0052] Oridonin A

10.0g

2,6-Dimethyl-β-cyclodextrin

20.0g

ethanol

20ml

Water for Injection

300ml

[0053] The preparation method of cyclodextrin inclusion compound is as follows:

[0054] Weigh 10.0g of Rubescensine A, dissolve in 20ml of ethanol; weigh 20.0g of 2,6-dimethyl-β-cyclodextrin, dissolve in 300ml of water for injection (deionized water can also be used) . After the two were mixed, the reaction was stirred for 4 hours, the temperature was controlled at about 60° C., and the reaction was stirred for 4 hours. Let it stand for 3 days, filter, and dry it.

[0055] Solubility test results show that the solubility of the clathrate is more than 10 times higher than that of oridonin. Stability after exposure to light is also significantly improved.

Embodiment 2

[0056] Example 2 Preparation of Oridonin A Cyclodextrin Inclusion Compound

[0057] Oridonin A

[0058] Refer to Example 1 for the preparation process.

Embodiment 3

[0059] Example 3 Preparation of Rubescensin A Cyclodextrin Inclusion Compound

[0060] Oridonin A

[0061] Refer to Example 1 for the preparation process.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An inclusion compound of rebescensine A is prepared from the rebescensine A as active component and cyclodextrin as including material in the weight ratio of 1: (0.5-50). A medicine containing said inclusion compound is also disclosed.

Description

technical field [0001] The invention relates to a pharmaceutical preparation of oridonin A as a therapeutic active ingredient, in particular to an inclusion compound of oridonin obtained by adopting cyclodextrin inclusion technology and related pharmaceutical preparations prepared by using the inclusion compound. Background technique [0002] Oridonin A is an alkene diterpene extracted from Oridonin grass. Rabdosiarubescens (Hemsl) Hara, also known as broken mia, snowflake grass, is a plant of the genus Coriander in the Lamiaceae family. It is a traditional Chinese herbal medicine that has the effects of clearing heat, detoxifying, reducing inflammation and relieving pain. In 1991, the Ministry of Health of my country approved its dried leaves and aerial parts as Chinese herbal medicines, which were included in the Ministry of Health's standards for Chinese herbal medicines. Since the 1970s in my country, a lot of research has been done on the chemical constituents, pharmac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K47/40A61K9/08A61K9/10A61K9/16A61K9/20A61K9/48A61P35/00
Inventor 贾志丹王洪钟袁宜耘李秀才王淑娟
Owner SINOPHARM A THINK PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products